As targeted therapies in colorectal, gastroesophageal, biliary tract, and other gastrointestinal (GI) cancers continue to gain traction, and as additional therapeutic targets for novel agents emerge, consistently testing for biomarkers will be key to identifying more targetable alterations for novel therapeutics and determining which patients will benefit most from these therapies, according to E. Gabriela Chiorean, MD.
With the November 16, 2023, FDA approval of pembrolizumab (Keytruda) plus fluoropyrimidine- and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma,1 another immunotherapy option has joined nivolumab (Opdivo) in the treatment paradigm.2
When considering how to best incorporate recently approved agents into care, Chiorean explained that pembrolizumab plus fluoropyrimidine- and platinum-based chemotherapy adds to the immune checkpoint inhibitor data that investigators already have with nivolumab. The 2021 approval of nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy for patients with advanced or metastatic gastric cancer, GEJ cancer, and esophageal adenocarcinoma was supported by findings from the phase 3 CheckMate 649 study (NCT02872116). Patients with a combined positive score (CPS) of at least 5 who received the combination experienced a statistically significant improvement vs chemotherapy alone in progression-free survival (HR, 0.68; 95% CI, 0.58-0.79; P< .0001) and overall survival (OS; HR 0.71; 95% CI, 0.61-0.83; P< .0001). Irrespective of CPS score, all patients receiving the combination achieved a statistically significant improvement vs chemotherapy alone in OS (HR, 0.80; 95% CI, 0.71-0.90; P=.0002).2
Nivolumab has been approved [by the FDA] for patients with HER2-negative gastroesophageal cancer [and its] mostly used for patients with [a] CPS of more than 5, Chiorean said in an interview with OncologyLive. Chiorean is a full professor of medicine at the University of Washington, clinical director of the GI Medical Oncology Program at Fred Hutchinson Cancer Center, and director of the Clinical Research GI Oncology Program at the University of Washington/Fred Hutchinson Cancer Center in Seattle.
Pembrolizumab has been approved irrespective of CPS, but we are very aware that the benefit is mostly for patients with a CPS higher than 1 or even higher than 10, she explained. Immunotherapies for advanced gastroesophageal cancers do apply for those with positive PD-L1 expression, whether its a CPS score more than 1, more than 5, or more than 10, depending on what immune checkpoint inhibitors we use.
As gene alterations become more prevalent therapeutic targets, DNA and RNA testing is of the upmost importance. Findings from a diagnostic study published in JAMA Oncology examining paired DNA and RNA sequencing of 43,524 individuals who underwent germline testing for hereditary cancer revealed that RNA evidence was necessary for the classification of 17.1% of pathogenic or likely pathogenic splicing variants. Additionally, 71.1% of existing splicing variants of uncertain significance were resolved by evidence from RNA tests. Investigators concluded that concurrent RNA and DNA sequencing improves detection of novel variants and classification of existing ones.3
Its exciting to apply these new therapeutics based on the targeted alterations that we findwe just have to test everybody, Chiorean said. We also have to be very careful to include both DNA testing as well as RNA testing because we may miss certain genetic alterations if we exclusively use DNA tests. There are RNA-based tests that can be more effective in finding genetic fusions, such as NRG1 fusions and RET fusions. These fusions are important because now we have agents targeting them.
Pralsetinib (Gavreto) and selpercatinib (Retevmo) are both targeted agents included in the National Comprehensive Cancer Network guidelines for the treatment of patients with unresectable and metastatic biliary tract cancers with RET fusions.4 Additionally, selpercatinib holds an indication for patients with locally advanced or metastatic solid tumors with RET fusions who have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.5
We need to make sure we test [for] everythingmicrosatellite instability[MSI] status, tumor mutational burden, DNA, and RNAin order to discover all the possible targetable alterations of our patients, because there are more and more treatments available, both in clinical trials and with FDA approvals.... Every tumor needs to be sequenced and when its not available we need to test [for] these molecular abnormalities with liquid biopsies [and] with circulating tumor [ct]DNA, Chiorean said.
Approximately 50% of patients with colorectal cancer (CRC) will develop colorectal liver metastasesclinically heterogeneous lesions associated with poor prognosis.6,7 In a retrospective study conducted in China that examined the genomic alterations of CRC liver metastases in 144 patients using next-generation sequencing, investigators found that the most prevalent alterations were TP53 (83%), APC (69%), KRAS (43%), and SMAD4 (17%).7
We know that certain cancers are more likely to shed ctDNA in the bloodpancreatic cancer tends to be a cancer [that is] less positive [for] ctDNA, but in CRCs, especially in those with liver metastases, liquid biopsies are very useful, Chiorean said.
Shooting For The Stars With Biomarkers
Moreover, we are trying to conduct more tests regarding how we can declare whether the patient is immune competent vs not. How do we determine the immune microenvironment that could be more amenable to be targeted with immunotherapies or not? Chiorean asked. These are very new biomarkers, which are not genetic based; they are more [representative of] a profile having to do with a tumor microenvironment and the host that the patient represents. We are doing a lot of research in this arena in terms of finding new markers for immune therapeutics [and] for stroma-targeted therapies.
In addition to the GI biomarkers of HER2 overexpression, MSI-high status, and PD-L1 expression, emerging biomarkers include CLDN18.2, which is present in approximately 30% of gastric/GEJ cancers, and FGFR2, which is rarer and reported in approximately less than 10% of gastric cancers.8
In July 2023, the FDA granted priority review to the biologics license application seeking the approval of the first-in-class monoclonal antibody zolbetuximab for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma and CLDN18.2-positive tumors.9
Additionally, in April 2021, the novel FGFR2 inhibitor bemarituzumab plus modified fluoropyrimidine, leucovorin, and oxaliplatin (mFOLFOX6) received breakthrough therapy designation from the FDA for the frontline treatment of patients withFGFR2b-overexpressing, HER2-negative metastatic and locally advanced gastric and GEJ adenocarcinoma following positive results from the phase 2 FIGHT study (NCT03694522).10 Bemarituzumab is currently under investigation with mFOLFOX6 in the phase 3 FORTITUDE-101 trial (NCT05052801) and with mFOLFOX6 and nivolumab in the phase 3 FORTITUDE-102 trial (NCT05111626).10
In addition, because [we can make] adoptive immunotherapies more active and reactive against the patients cancer using the patients human leukocyte antigen [HLA] testing, HLA testing is becoming more important. Knowing the proteins that present an antigen to the immune system such that patients may become able to participate in adoptive immunotherapy trials [is important]. Biomarkers are being extended beyond next-generation sequencing, Chiorean noted.
Chiorean noted that upcoming presentations at the 9th Annual School of Gastrointestinal Oncology (SOGO), which is scheduled to take place on February 24, 2024, in Los Angeles, California, will address these novel treatment options in addition to various aspects of multidisciplinary care, ranging from the nonoperative or operative management of stage IV CRC to using targeted [therapy] and/or immunotherapy in early-stage gastroesophageal as well as hepatobiliary cancers. [The treatment of patients with] hepatobiliary cancers is typically very multidisciplinary because it involves surgery, interventional radiology, radiation oncology, and medical oncology.
The American Cancer Society listed 11 regimens used to treat stage IV colon cancer in August 2023, noting that these were only some of the most commonly used regimens. Radiation and surgery were also cited as options in certain cases.11
A lot of debate exists in terms of managing stage IV CRC that has been resected, oligometastatic disease that has been resected, [and] the role of ctDNA. These sessions will be of huge interest [at SOGO 2024] in order to understand the players that have to be engaged in making treatment decisions for our patients, Chiorean said.
At SOGO 2024, sessions will include The Role of ctDNA in Colon Tumor Management presented by Sidharth R. Anand, MD, MBA, who is a medical oncologist and hematologist at UCLA Health in Los Angeles, California, and Management of Stage IV no evidence of disease [NED] CRC presented by Marwan G. Fakih, MD, who is a medical oncologist, professor in the Department of Medical Oncology & Therapeutics Research, associate director for Clinical Sciences, medical director of the Briskin Center for Clinical Research, division chief of GI Medical Oncology, and co-director of the Gastrointestinal Cancer Program, all at City of Hope in Duarte, California.
[We] are looking at the RAS inhibitors, pan-RAS inhibitors, [and] KRAS G12C inhibitors, both as monotherapy as well as in combination therapies, Chiorean noted. Certainly, were also looking at cancer vaccines [and] at oncolytic viruses. These are very exciting agents that may [become a part of] combination therapeutics with immune checkpoint inhibitors or even chemotherapies. Indeed, there are several classes of agents, both targeted as well as immune-based therapies, that are very exciting and I look forward to 2024 [to see] more, hopefully positive results.
View post:
Discovering Fusions Requires More Than DNA Testing in GI Cancers - OncLive
- DNA identifies last known remains of victims of notorious Green River Killer, cops say - Miami Herald - January 23rd, 2024 [January 23rd, 2024]
- UNE to study why rare lobsters have strange-colored shells - Spectrum News - January 23rd, 2024 [January 23rd, 2024]
- DNA evidence identifies last known victim of Green River Killer almost 40 years later - NBC Right Now - January 23rd, 2024 [January 23rd, 2024]
- New bill would give California parents more control over whether state can store their kid's DNA - CBS News - January 23rd, 2024 [January 23rd, 2024]
- Lucas County Sheriff's Office doing advanced testing on DNA found at site of 2011 Clarke and Straub murders - WTOL - January 23rd, 2024 [January 23rd, 2024]
- Last known remains connected to the Green River Killer identified through DNA | WTGS - Fox28 Savannah - January 23rd, 2024 [January 23rd, 2024]
- 5 Best Ancestry DNA Tests 2024 To Help You Learn More About Your Health - GLAMOUR UK - January 23rd, 2024 [January 23rd, 2024]
- 11 Investigates: Lucas County Sheriff's Office doing advanced testing on DNA found at site of 2011 Clarke and Straub murders - WTOL - January 23rd, 2024 [January 23rd, 2024]
- Researchers improve blood tests' ability to detect and monitor cancer - MIT News - January 23rd, 2024 [January 23rd, 2024]
- DNA test approved for Duxbury's Lindsay Clancy, who is accused of killing her 3 children - The Patriot Ledger - January 23rd, 2024 [January 23rd, 2024]
- 1,650th victim of 9/11 identified through advanced DNA testing - FOX 17 West Michigan News - January 23rd, 2024 [January 23rd, 2024]
- We Think Cavco Industries (NASDAQ:CVCO) Might Have The DNA Of A Multi-Bagger - Yahoo Finance - January 23rd, 2024 [January 23rd, 2024]
- DNA From the Ocean's 'Twilight Zone' Could Lead to New Lifesaving Drugs, Scientists Say - Smithsonian Magazine - January 23rd, 2024 [January 23rd, 2024]
- Last known remains connected to the Green River Killer identified through DNA - KOMO News - January 23rd, 2024 [January 23rd, 2024]
- 9/11 victim identified as John Ballantine Niven of Oyster Bay with help of DNA technology - WABC-TV - January 23rd, 2024 [January 23rd, 2024]
- Scott Peterson has every right to DNA test: Attorney from case - NewsNation Now - January 23rd, 2024 [January 23rd, 2024]
- DNA from stone age chewing gum sheds light on diet and disease in Scandinavia's ancient hunter-gatherers - The Conversation - January 23rd, 2024 [January 23rd, 2024]
- Barbara Lee responds to Nikki Haley: Racism is in the DNA of this country - The Hill - January 23rd, 2024 [January 23rd, 2024]
- DB Cooper 'will finally be identified' after 53 years due to huge DNA breakthrough - LADbible - January 23rd, 2024 [January 23rd, 2024]
- Dog Owners Who Abandon Poops To Be Found Using DNA Tests in Italy - Newsweek - January 23rd, 2024 [January 23rd, 2024]
- Scientists gather bobcat DNA from paw prints - KJZZ - January 16th, 2024 [January 16th, 2024]
- Largest-ever ocean DNA study uncovers mysteries of marine life - Earth.com - January 16th, 2024 [January 16th, 2024]
- 1st-ever ancient case of Turner syndrome, with just 1 X chromosome instead of 2, found in ancient DNA - Livescience.com - January 16th, 2024 [January 16th, 2024]
- Minnesota Mother Calls on NYS to Allow DNA Testing Finger Lakes Daily News - Finger Lakes Daily News - January 16th, 2024 [January 16th, 2024]
- DNA Didn't Match Marcellus Williams. Missouri May Fast-Track Execution Anyway. - The Intercept - January 16th, 2024 [January 16th, 2024]
- Ancient DNA From Eurasian Herders Sheds Light on the Origins of Multiple Sclerosis - Smithsonian Magazine - January 16th, 2024 [January 16th, 2024]
- DNA's hotel toh kuyabeh mirrors bird flight undulations in tulum - Designboom - January 16th, 2024 [January 16th, 2024]
- Research into ancient DNA sheds new light on cause of Multiple Sclerosis and other neurodegenerative diseases - University of Oxford - January 16th, 2024 [January 16th, 2024]
- Ancient DNA reveals reason for high MS and Alzheimer's rates in Europe - University of Cambridge news - January 16th, 2024 [January 16th, 2024]
- TIME-seq reduces time and cost of DNA methylation measurement for epigenetic clock construction - Nature.com - January 16th, 2024 [January 16th, 2024]
- Gilgo Serial Killer Suspect Rex Heuermann Tied to Slaying by DNA From Daughter's Can of Coffee: Prosecutors - The Messenger - January 16th, 2024 [January 16th, 2024]
- DNA evidence leads to arrest of Denton sexual assault suspect - The Cross Timbers Gazette - January 16th, 2024 [January 16th, 2024]
- Ancient DNA reveals reason for high multiple sclerosis and Alzheimer's rates in Europe - EurekAlert - January 16th, 2024 [January 16th, 2024]
- New technique identifies earliest cases of genetic disorders from ancient DNA - University of Oxford - January 16th, 2024 [January 16th, 2024]
- Ancient DNA could be hiding all kinds of health secrets - Deccan Herald - January 16th, 2024 [January 16th, 2024]
- Ancient DNA reveals reason for high MS and Alzheimer's rates in Europe - ScienceBlog.com - January 16th, 2024 [January 16th, 2024]
- Supreme Court seeks government's view on DNA profiling of unidentified bodies - IndiaTimes - January 16th, 2024 [January 16th, 2024]
- Prosecution Ordered to Release Portion of DNA Evidence to Kohberger's Defense Team - bigcountrynewsconnection.com - January 16th, 2024 [January 16th, 2024]
- Judge orders more DNA disclosure in University of Idaho murder case - KXLY Spokane - January 16th, 2024 [January 16th, 2024]
- Cas9-induced targeted integration of large DNA payloads in primary human T cells via homology-mediated end-joining ... - Nature.com - December 14th, 2023 [December 14th, 2023]
- The DNA glycosylase NEIL2 is protective during SARS-CoV-2 infection - Nature.com - December 14th, 2023 [December 14th, 2023]
- How an immune response is driven by one letter difference in DNA - Medical Xpress - December 14th, 2023 [December 14th, 2023]
- Tracy Morgan Discovered He Was Related to Nas After DNA Test - PEOPLE - December 14th, 2023 [December 14th, 2023]
- Scientists testify about DNA in third week of Aguirre trial - The Spokesman Review - December 14th, 2023 [December 14th, 2023]
- DNA metabarcoding focusing on the plankton community: an effective approach to reconstruct the paleo-environment ... - Nature.com - December 14th, 2023 [December 14th, 2023]
- Advancement in DNA Technology and Tenacity of Cold Case Detective Identifies Victim in 37-year-old Homicide - hellowoodlands.com - December 14th, 2023 [December 14th, 2023]
- Integrating DNA methylation and gene expression data in a single gene network using the iNETgrate package ... - Nature.com - December 14th, 2023 [December 14th, 2023]
- Forensic scientist testifies about evidence contamination at state lab in 1986, says knowledge of DNA has since ... - The Spokesman Review - December 14th, 2023 [December 14th, 2023]
- Tracy Morgan Discovers He Is Related To Nas Through DNA Test - BET - December 14th, 2023 [December 14th, 2023]
- DNA discovery opens door to tailored medicine for Indigenous Australians | Australian National University - ANU - December 14th, 2023 [December 14th, 2023]
- Tracy Morgan Started Crying After Learning Hes Related To Nas Through A DNA Test - TODAY - December 14th, 2023 [December 14th, 2023]
- Electric eel zaps do more than just stun they can alter the DNA of their victims, study suggests - Salon - December 14th, 2023 [December 14th, 2023]
- Blueface Says He Took a DNA Test That Proves He's Not the Father of Chrisean Rock's Son: 'Thank You Jesus' - Complex - December 14th, 2023 [December 14th, 2023]
- Altina Wildlife Park to use DNA tests to find mystery father of black-and-white ruffed lemur triplets - ABC News - December 14th, 2023 [December 14th, 2023]
- In the Shadow of Rome: Ancient DNA Recasts Balkan History - SciTechDaily - December 14th, 2023 [December 14th, 2023]
- Even microbes felt the impact of ancient climate transitions, McMaster DNA researchers find - Brighter World - December 14th, 2023 [December 14th, 2023]
- Clarence 'Red' Wilson cold case murder: DNA helps Montgomery County detective break 37-year unsolved Texas homicide - KTRK-TV - December 14th, 2023 [December 14th, 2023]
- How Construction Companies Can Make Diversity Part of Their DNA - For Construction Pros - December 14th, 2023 [December 14th, 2023]
- DNA analysis of bat droppings shows astonishingly high number of insect species - Phys.org - December 14th, 2023 [December 14th, 2023]
- Co-Lin football's blue-collar DNA on display in huge road win at Gulf ... - Dailyleader - October 13th, 2023 [October 13th, 2023]
- DNA methylation: The hidden mechanism enabling plants to adapt ... - EurekAlert - October 13th, 2023 [October 13th, 2023]
- Neanderthals carried genes acquired from ancient interactions with ... - Penn Today - October 13th, 2023 [October 13th, 2023]
- DNA meythlation clocks and their limitations - Lifespan.io News - October 13th, 2023 [October 13th, 2023]
- Neanderthal DNA may shape how sensitive you are to pain, genetic ... - Livescience.com - October 13th, 2023 [October 13th, 2023]
- OvaPrint a cell-free DNA methylation liquid biopsy for the risk ... - Cancer Discovery - October 13th, 2023 [October 13th, 2023]
- After being freed once, Ohio man languishes on death row - Ohio Capital Journal - October 13th, 2023 [October 13th, 2023]
- Maximizing ROI With Cattle DNA Testing - AG INFORMATION ... - AGInfo Ag Information Network - October 13th, 2023 [October 13th, 2023]
- Pittsburgh's Opening Night Roster Stays True to Its DNA | Pittsburgh ... - NHL.com - October 13th, 2023 [October 13th, 2023]
- Indonesia turns to DNA technology to save their sharks - Earth.com - October 13th, 2023 [October 13th, 2023]
- There are 750 unidentified human remains in Australia. Could your ... - The Conversation - October 13th, 2023 [October 13th, 2023]
- Baltimore Witness - Baltimore Witness - October 13th, 2023 [October 13th, 2023]
- DNA Chips: The Billion Gigabyte Storage Solution of Tomorrow - SciTechDaily - September 9th, 2023 [September 9th, 2023]
- DNA's 'topography' influences where cancer-causing mutations appear - Livescience.com - September 9th, 2023 [September 9th, 2023]
- Dog diversity unveiled by international DNA database - Science Daily - September 9th, 2023 [September 9th, 2023]
- DNA from UW student attack 'one in one quadrillion' match to suspect - The Capital Times - September 9th, 2023 [September 9th, 2023]
- Invitation: TAG Heuer popup to showcase its DNA and motorsports - - Deployant - September 9th, 2023 [September 9th, 2023]
- Ancient Clostridium DNA and variants of tetanus neurotoxins ... - Nature.com - September 9th, 2023 [September 9th, 2023]
- DNA methylation and the opposing NMDAR dysfunction in ... - Nature.com - September 9th, 2023 [September 9th, 2023]
- 'I don't think it's in her DNA': Man who co-authored Murdaugh book with Colleton Co. Clerk of Court discusses allegations - ABC NEWS 4 - September 9th, 2023 [September 9th, 2023]
- Using DNA to solve a family mystery: 'It brought great comfort to ... - The Irish Times - September 9th, 2023 [September 9th, 2023]